A double-blind placebo-controlled crossover study finds metformin attenuates the postprandial blood pressure fall and reduces postprandial hypotension events in type 2 diabetes, alongside higher GLP-1, slower gastric emptying, and a faster heart rate. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
An exploratory post hoc analysis suggesting tirzepatide improves insulin sensitivity more per unit weight loss than semaglutide in type 2 diabetes. PICO summary and expert commentary.
In QWINT-3, once-weekly insulin efsitora alfa was non-inferior to once-daily degludec for HbA1c lowering in basal-insulin-treated type 2 diabetes, with comparable hypoglycaemia. PICO summary and expert commentary.
QWINT-4 phase 3 trial: once-weekly insulin efsitora alfa was non-inferior to daily glargine U100 for HbA1c in basal-prandial-treated type 2 diabetes. PICO summary and expert commentary.
A 10-week whole-food plant-based community programme produced significant between-group weight loss but no significant glycaemic or lipid change in this small New Zealand RCT. PICO summary and expert commentary.
A post hoc analysis of the DIVERSITY-CVR trial tests whether baseline ALT predicts differential HbA1c and time-in-range responses to dapagliflozin versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
An early-phase trial of the GLP-1/FGF21 dual agonist HEC88473 reported dose-proportional liver fat reduction and improved glycaemic control over 5 weeks in patients with MASLD and type 2 diabetes. PICO summary and expert commentary.
A 12-week four-arm randomised trial in 36 male recreational athletes found that combined diet plus exercise improved body composition and glycaemic markers, with small effect sizes. PICO summary and expert commentary.
A secondary analysis of the VA NEPHRON-D cohort found that higher baseline urinary EGF and uromodulin were independently associated with a lower risk of diabetic kidney disease progression. PICO summary and expert commentary.
Once-weekly fixed-dose insulin efsitora was noninferior to once-daily glargine for HbA1c reduction over 52 weeks in insulin-naive type 2 diabetes, with less hypoglycaemia. PICO summary and expert commentary.